InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Rhea-AI Summary

Shoulder Innovations (NYSE: SI) announced the full commercial launch of the InSet™ 70 humeral stem on Sept. 22, 2025 in Grand Rapids, Mich.

The InSet™ 70 expands the company’s I-Series humeral stem line (which began with the InSet™ 95 in 2024), is cleared for both anatomic and reverse shoulder arthroplasty, and addresses indications including osteoarthritis, avascular necrosis, rheumatoid and traumatic arthritis, irreparable cuff tears, and certain revision cases.

Company statements highlight the InSet™ 70’s bone-sparing design, initial fixation comparable to the longer InSet™ 95, simplified surgical workflow, and claimed optimized biomechanics intended to support improved shoulder function for patients.

Expansion of the I-Series Humeral Stem Product Line Further Strengthens Robust Shoulder Arthroplasty Portfolio

GRAND RAPIDS, Mich., Sept. 22, 2025 /PRNewswire/ -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the full commercial launch of the InSet™ 70 Humeral Stem ("InSet™ 70"). The introduction of the InSet™ 70 represents an expansion of the company's I-Series humeral stem product line, which first launched with the InSet™ 95 humeral stem in 2024.

This expansion of the I-Series Humeral Stem product line further strengthens a robust Shoulder Arthroplasty portfolio.

"The InSet™ 70 complements our broad portfolio of advanced shoulder implant solutions, and we are excited to bring it to market across the United States ahead of schedule," said Rob Ball, CEO of Shoulder Innovations. "SI has a strong history of innovation, and the InSet™ 70 is another example of new technology designed to enhance the quality of care for patients and provide meaningful value to the surgeons who care for them. We look forward to seeing improved patient outcomes and long-term function with this implant."

Indicated for use in both anatomic and reverse shoulder arthroplasty, the InSet™ 70 addresses a broad range of clinical needs, including non-inflammatory degenerative joint disease such as osteoarthritis and avascular necrosis, rheumatoid and traumatic arthritis, and correction of functional deformity. In reverse procedures, it is further indicated for irreparable cuff tears with or without arthritis, as well as for revision of other devices when sufficient bone stock remains.

"Featuring the same excellent initial fixation and simple workflow as the longer InSet™ 95, the InSet™ 70 offers the added benefit of bone-sparing utility, making it a compelling offering in the shoulder care space," said Galen Kam, MD. "Essentially, this product affords all the advantages of a larger stem in a smaller, bone-preserving form factor."

"The InSet™ 70 provides my patients with superb humeral fixation within the reverse total shoulder platform, delivering optimized biomechanics and supporting improved shoulder function," said Matthew Pifer, MD.

About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations' ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations' ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.

Contact 
Brian Johnston or Sam Bentzinger
Gilmartin Group LLC
ir@shoulderinnovations.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/shoulder-innovations-announces-full-commercial-launch-of-the-inset-70-humeral-stem-302562301.html

SOURCE Shoulder Innovations

FAQ

What is the InSet™ 70 launched by Shoulder Innovations (NYSE: SI) on Sept. 22, 2025?

The InSet™ 70 is a new humeral stem in the I-Series, launched commercially in the U.S. and intended for anatomic and reverse shoulder arthroplasty.

How does the InSet™ 70 differ from the InSet™ 95 from 2024?

The InSet™ 70 offers a shorter, bone-sparing form factor while maintaining the company’s stated excellent initial fixation and simple workflow similar to the InSet™ 95.

What clinical indications does the InSet™ 70 cover for SI (NYSE: SI)?

Indications include non-inflammatory degenerative joint disease like osteoarthritis and avascular necrosis, rheumatoid and traumatic arthritis, irreparable cuff tears, and certain revision cases when sufficient bone stock remains.

When and where was Shoulder Innovations’ InSet™ 70 announced?

The company announced the full commercial launch on Sept. 22, 2025 in Grand Rapids, Michigan.

Will the InSet™ 70 be available across the United States immediately?

The company said the InSet™ 70 is being brought to market across the United States and was launched ahead of schedule.

What benefits did surgeons cite for the InSet™ 70 in the Sept. 22, 2025 announcement?

Surgeons cited bone-sparing utility, superb humeral fixation within reverse platforms, optimized biomechanics, and potential for improved shoulder function.